HAEMATO AG Stock Deutsche Boerse AG

Equities

HAEK

DE000A289VV1

Pharmaceuticals

Market Closed - Deutsche Boerse AG 09:47:18 2024-04-17 EDT 5-day change 1st Jan Change
15.05 EUR +0.33% Intraday chart for HAEMATO AG +0.33% -44.26%
1 week+0.33%
Current month+0.33%

Financials

Sales 2023 * 268M 288M 395M Sales 2024 * 281M 302M 415M Capitalization 88.87M 95.42M 131M
Net income 2023 * 7M 7.52M 10.33M Net income 2024 * 10M 10.74M 14.75M EV / Sales 2023 * 0.25 x
Net cash position 2023 * 21.2M 22.77M 31.28M Net cash position 2024 * 24.2M 25.99M 35.7M EV / Sales 2024 * 0.23 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 76
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.33%
1 week+0.33%
Current month+0.33%
1 month+0.33%
3 months-9.88%
6 months-44.26%
Current year-44.26%
More quotes
Current year
14.40
Extreme 14.4
27.60
1 year
14.40
Extreme 14.4
27.60
3 years
14.40
Extreme 14.4
27.60
5 years
14.40
Extreme 14.4
27.60
10 years
14.40
Extreme 14.4
27.60
More quotes
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise